FLT3-Mutated AML / Leukemia 07/23/2026

Ep. 1: Optimizing FLT3-Mutated AML Through Precision Testing and Targeted Therapy

Healthy woman smiling with dark hair and white coat, healthcare professional, medical environment, oncology specialist, cancer treatment, OncUpdates, medical research, patient care, healthcare provider, medical expert. Uma Borate, MBBS A professional male doctor in a suit, smiling confidently against a neutral background, representing oncology and cancer treatment expertise. Naval Daver, MD Professional portrait of a smiling man in a dark suit and blue tie, with a neutral gray background, suitable for medical or corporate profiles. Nicholas Short, MD Smiling man with beard wearing a white shirt, professional headshot, suitable for oncology or cancer research content, emphasizing healthcare and medical expertise. Rahul Gosain, MD, MBA Oncologist smiling in white coat, highlighting cancer research and treatment expertise, with a bow tie, in a bright medical setting. Rohit Gosain, MD

Key Points

  • FLT3 mutations occur in approximately 20% to 30% of younger patients with acute myeloid leukemia (AML) and should be assessed at diagnosis and again at relapse to guide treatment decisions.
  • Improvements in FLT3 inhibitors, measurable residual disease (MRD) assessment, and transplant strategies have significantly changed the prognosis for patients with FLT3-mutated AML.
  • Second-generation FLT3 inhibitors have become integral across the disease continuum.

During a recent Clinical Insights discussion, Oncology Brothers podcast cohosts Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, and Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, were joined by Uma Borate, MBBS, of The Ohio State University, and Naval Daver, MD, and Nicholas Short, MD, both of The University of Texas MD Anderson Cancer Center, to discuss the evolving management of FLT3-mutated AML. The panel explored current recommendations for molecular testing, evolving strategies for prognostic risk assessment, and FLT3 inhibitors’ growing role across multiple treatment settings.

Dr. Borate emphasized that FLT3 mutations are identified in approximately 20% to 30% of younger patients with AML, with internal tandem duplication (ITD) mutations occurring more frequently than tyrosine kinase domain (TKD) mutations. The panel stressed that FLT3 testing should be performed at initial diagnosis to guide frontline treatment selection and repeated at relapse, as the mutations may be acquired or lost during disease evolution. Although intensive induction chemotherapy followed by consideration of allogeneic stem cell transplantation remains a standard approach for eligible patients, molecular profiling has become increasingly important for incorporating targeted therapies into treatment plans.

The discussion included the evolving prognostic significance of FLT3 mutations. Historically considered an adverse-risk feature, FLT3-ITD AML is now recognized as having a more nuanced prognosis influenced by co-occurring mutations, MRD status, and treatment approach.

Dr. Borate noted that current European LeukemiaNet classifications account for these variables, particularly the presence of NPM1 comutations. Dr. Daver added that advances in supportive care, earlier intervention, routine incorporation of FLT3 inhibitors, and improved transplant strategies have dramatically improved outcomes. Dr. Short further discussed emerging evidence suggesting that select patients with FLT3-ITD and NPM1 comutated disease who achieve deep MRD negativity after induction therapy may be able to avoid allogeneic transplantation, although additional prospective data are needed before this approach becomes routine clinical practice.

The panel concluded by reviewing the expanding role of FLT3 inhibitors across the treatment continuum. Dr. Daver described the evolution from first-generation agents such as midostaurin to more potent second-generation inhibitors, including quizartinib and gilteritinib. The experts emphasized the importance of understanding the biologic differences between FLT3 mutation subtypes when selecting therapy. Quizartinib has demonstrated improved survival when combined with induction chemotherapy in newly diagnosed FLT3-ITD AML, whereas gilteritinib remains a cornerstone therapy for relapsed or refractory disease because it targets both ITD and TKD mutations.